Research programme: G protein-coupled receptor-targeted antibody - Debiopharm/MSM Protein TechnologiesAlternative Names: Debio 0929
Latest Information Update: 16 Jul 2016
At a glance
- Originator Debiopharm Group; MSM Protein Technologies
- Class Antibodies
- Mechanism of Action G protein-coupled receptor modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in USA (Parenteral)
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in Switzerland (Parenteral)
- 30 Jul 2009 Early research in Cancer in USA (Parenteral)